Loading...
Market
What will be the outcome of BioNTech's mRNA lung cancer vaccine BNT116 clinical trial by December 31, 2024?
2
Resolution / Starting Odds
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Clinical trial results published in peer-reviewed journals
Story
67-Year-Old UK Patient First to Receive BioNTech's mRNA Lung Cancer Vaccine
Aug 23, 2024, 10:33 AM
A 67-year-old man named Janusz Racz has become the first person in the UK to receive a pioneering lung cancer vaccine as part of a clinical trial. This vaccine, developed by the German biotechnology firm BioNTech and known as BNT116, is an mRNA-based treatment that works by priming the immune system to recognize and fight cancer cells. The trial, which is a world-first for an mRNA lung cancer vaccine, is being conducted across seven countries and involves 34 international research sites, including University College London, and will recruit 130 patients. The vaccine is seen as a potential breakthrough in the fight against lung cancer, offering hope for a treatment that could save thousands of lives.
View original story
Similar markets
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Hold Lifted • 33%
Hold Extended • 33%
New Restrictions • 34%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Dose escalation • 25%
Safety assessment • 25%
Efficacy assessment • 25%
Trial termination • 25%
UK • 14%
Germany • 14%
USA • 14%
France • 14%
Italy • 14%
Spain • 14%
Other • 14%